SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001420720-22-000054
Filing Date
2022-09-27
Accepted
2022-09-27 16:11:20
Documents
14
Period of Report
2022-09-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20220927x8k.htm   iXBRL 8-K 39766
2 EX-99.1 ibio-20220927xex99d1.htm EX-99.1 25177
  Complete submission text file 0001420720-22-000054.txt   199666

Data Files

Seq Description Document Type Size
3 EX-101.SCH ibio-20220927.xsd EX-101.SCH 4009
4 EX-101.DEF ibio-20220927_def.xml EX-101.DEF 3279
5 EX-101.LAB ibio-20220927_lab.xml EX-101.LAB 14109
6 EX-101.PRE ibio-20220927_pre.xml EX-101.PRE 10629
8 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20220927x8k_htm.xml XML 4805
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

IRS No.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 221271193
SIC: 2834 Pharmaceutical Preparations